HIV

The Pharmacy Times® human immunodeficiency virus (HIV) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
A new study found that it’s safe for patients with HIV to receive HIV-positive kidneys. 
[[thumbnail_alt_text]]
As patients return to their routines of returning to pharmacies and the inevitable discussions about COVID-19 begin, it may be a good time to discuss the range of tests that the CDC recommends.
[[thumbnail_alt_text]]
Globally, dolutegravir is expected to be a part of treatment for approximately 15 million people living with HIV by 2021.
[[thumbnail_alt_text]]
Significant morbidity and mortality are associated with an aging population due to cardiovascular disease, which is very common in HIV-infected persons.
[[thumbnail_alt_text]]
Fostemsavir is indicated for adults with drug resistant HIV.
[[thumbnail_alt_text]]
Dolutegravir tablets are intended to treat pediatric patients at least 4 weeks old and at least 6 pounds who have never been treated for HIV or who have been treated, but not with an integrase strand transferase inhibitor class drug, according to the press release.
 
[[thumbnail_alt_text]]
New research on the structure of HIV has revealed a promising novel drug target for treating HIV infection.
[[thumbnail_alt_text]]
Today, we’re celebrating the clinical pharmacy specialist team at the William J. Holloway Community Program in Delaware.
 
[[thumbnail_alt_text]]
The 2 most common, recommended, and simplified treatments for HCV are glecaprevir/pibrentasvir (Mavyret) and sofosbuvir/velpatasvir (Epclusa).
[[thumbnail_alt_text]]
The widely available anti-parasitic drug ivermectin is capable of killing COVID-19 within 48 hours in a cell culture, according to a new study.
 
[[thumbnail_alt_text]]
What would you recommend for these patients?
[[thumbnail_alt_text]]
A study of the second HIV patient to undergo successful stem cell transplantation from donors with an HIV-resistant gene found that there was no active viral infection in the patient’s blood 30 months after they stopped antiretroviral therapy.